Search Within

Lymphoma

Formats
  1. Meeting Abstract (1382)
  2. Journal Article (1057)
  3. Book Section (64)
  4. Review (64)
  5. Editorial (38)
  6. Research Letter (38)
  7. Guidelines (19)
  8. Conference Paper (15)
  9. Correspondence (12)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2698)
  2. Department of Medicine (2698)
  3. Hematologic Malignancies, Division of (2698)
  4. Population Sciences Research Program (744)
  5. Survivorship Research (655)
  6. Executive Committee, Center for Hematologic Malignancies (391)

More Groups

People
  1. Andrew Zelenetz (782)
  2. Steven Horwitz (666)
  3. Maria Palomba (445)
  4. Ariela Noy (371)
  5. David Straus (360)
  6. Alison Moskowitz (358)

More People

Years
  1. 2025 (45)
  2. 2024 (141)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (876)
  2. Journal of Clinical Oncology (277)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (83)
  5. British Journal of Haematology (81)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (941)
  2. American Society of Clinical Oncology (293)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (96)
  6. Nature Publishing Group (93)

More Publishers

Results (2698)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity
    Meeting Abstract

    Flinn, I.; Hamlin, P. A.; Strickland, D. K.; Pandey, A.; Birrell, M.; Coffey, G.; Leeds, J.; Curnutte, J. T.; Burger, J. A.; Wagner-Johnston, N. D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • CD30+ expression in peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project
    Meeting Abstract

    Federico, M.; Bellei, M.; Luminari, S.; Horwitz, S. M.; Montoto, S.; Zucca, E.; Pileri, S. A.; Ko, Y. H.; Zinzani, P. L.; Connors, J. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phenotypic correlation of tumor uptake of exogenous glutamine radiotracer versus tumor mutational status
    Meeting Abstract

    Dunphy, M.; Harding, J. J.; Lewis, J. S.; Mellinghoff, I. K.; Omuro, A. M. P.; Hsieh, J.; Zhang, H. W.; Zanzonico, P.; Venneti, S.; Carlin, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor
    Meeting Abstract

    Douglas, M.; Allen, K.; Sweeney, J.; O'Brien, S. M.; Flinn, I.; Horwitz, S. M.; Byrd, J. C.; Patel, M. R.; Kahl, B. S.; Foss, F. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials
    Meeting Abstract

    Coutre, S.; Barrientos, J. C.; Brown, J. R.; de Vos, S.; Furman, R. R.; Keating, M. J.; O'Brien, S. M.; Pagel, J. M.; Sharman, J. P.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Breast implant-associated anaplastic large cell lymphoma: Proposal for optimal management
    Meeting Abstract

    Clemens, M. W.; Butler, C. E.; Hunt, K.; Fanale, M. A.; Horwitz, S. M.; Liu, H.; Mccarthy, C.; Nastoupil, L. J.; Liu, J.; Medeiros, L. J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL)
    Meeting Abstract

    Chihara, D.; Pro, B.; Loghavi, S.; Miranda, R. N.; Medeiros, L. J.; Fanale, M. A.; Hagemeister, F. B.; Fayad, L.; Romaguera, J. E.; Samaniego, F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma
    Meeting Abstract

    Berdeja, J. G.; Oki, Y.; Patel, M. R.; Copeland, A.; Flinn, I.; Neelapu, S. S.; Viner, J.; Wang, J.; Gerecitano, J. F.; Younes, A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin's lymphoma (iNHL) in idelalisib (IDELA) trials
    Meeting Abstract

    Barrientos, J. C.; Ghia, P.; Pagel, J.; Salles, G. A.; Sharman, J. P.; Stilgenbauer, S.; Gurtovaya, O.; Kim, Y.; Philip, B.; Zelenetz, A. D.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Imaging for staging and response assessment in lymphoma
    Journal Article

    Johnson, S. A.; Kumar, A.; Matasar, M. J.; Schöder, H.; Rademaker, J.
    Radiology (2015)

    Fulltext@MSK | Save